Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology
+$0.09 today
- Market cap
- $254.64M
- Beta
- 0.01
- P/E (TTM)
- 11.0
- EPS (TTM)
- $0.19
Volume 0.96M
Average 0.81M
PLX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Protalix BioTherapeutics, Inc.AMEX: PLX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $6.41M, compared with -$2.28M a year earlier. Trailing-twelve-month accounts receivables was $2.79M. Over 3 fiscal years it compounded at +70.2% a year.
Context
- Accounts receivables amounted to 11.2% of revenue in FY2025, up 6.8 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $6.41M or moves back toward the trailing-twelve-month quarterly average of $698.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (5.89M) USD
- Year-over-year change
- -354.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.89M) | -354.2% |
| FY2024 | 2024-12-31 | 2.32M | +641.4% |
| FY2023 | 2023-12-31 | (428K) | +64.2% |
| FY2022 | 2022-12-31 | (1.19M) | -15.7% |
| FY2021 | 2021-12-31 | (1.03M) | — |
Accounts Receivables vs competitors
How PLX compares with its peers on the latest reported figures
- PLX's LTM Mar 2026 accounts receivables of $2.79M is the 3rd largest of the 4 companies compared; the peer median is $13.18M.
- Its year-over-year change of +263.9% is the highest of 3, against a peer median of -829.5%.
- Accounts receivables amounts to 3.7% of revenue for PLX, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.06M | -1708.0% | +37.0% | 3.3% | |
| LTM Mar 2026 | $13.18M | +49.0% | — | 3.6% | |
| LTM Mar 2026 | $2.79M | +263.9% | +70.2% | 3.7% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | $0 | — | — | — |
| Peer median (excluding PLX) | $13.18M | -829.5% | +37.0% | 3.4% | |
Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.58M) | (14.93M) | 8.31M | 2.93M | (6.6M) |
| Depreciation & Amortization | 1.12M | 1.09M | 1.19M | 1.3M | 1.47M |
| Deferred Income Tax | 0 | 0 | (3.09M) | 236K | 340K |
| Stock-Based Compensation | 2.38M | 2.09M | 3.45M | 3.25M | 2.3M |
| Change in Working Capital | 9.9M | (12.02M) | (10.54M) | 811K | (10.1M) |
| Accounts Receivables | (1.03M) | (1.19M) | (428K) | 2.32M | (5.89M) |
| Inventory | (4.87M) | 1.15M | (2.24M) | (2.2M) | (4.49M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 15.81M | (11.97M) | (7.87M) | 692K | 277K |
| Other Non-Cash Items | 3.9M | (1.23M) | (638K) | 138K | 608K |
| Operating Cash Flow | (10.29M) | (25M) | (1.32M) | 8.67M | (11.99M) |
| Capital Expenditures | (1.46M) | (628K) | (1.15M) | (1.28M) | (1.64M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (37.84M) | (16M) | (20.42M) | (15M) | (702K) |
| Sales of Investments | 57.84M | 11M | 5M | 20.42M | 0 |
| Other Investing Activities | 380K | 593K | (142K) | 83K | (26K) |
| Investing Cash Flow | 18.92M | (5.04M) | (16.71M) | 4.22M | (2.37M) |
| Debt Repayment | (34.12M) | 0 | 0 | (20.42M) | 0 |
| Common Stock Issued | 46.2M | 8.24M | 23.95M | 3.63M | 9.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 2K | 712K | 0 | 0 |
| Financing Cash Flow | 12.08M | 8.24M | 24.67M | (16.79M) | 9.33M |
| Effect of Forex Changes | 6K | (77K) | (114K) | 25K | 655K |
| Net Change in Cash | 20.72M | (21.87M) | 6.52M | (3.87M) | (4.38M) |
| Free Cash Flow | (11.74M) | (25.63M) | (2.47M) | 7.39M | (13.63M) |
Protalix BioTherapeutics, Inc.
AMEX:PLX
Intrinsic Alpha fair value
Locked
Current Price
$3.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.